Publications

Research outputs, reports, policy briefs and knowledge products from KIU scholars and partners.

2026 School of Pharmacy Research Output Journal of Biological and Applied Science

The Gut Microbiome in Obesity and Diabetes: Emerging Links and Modulation Strategies

Bwanbale Geoffrey David

The intestinal microbiome is a dense, metabolically active ecosystem that shapes host energy balance, immunity, and endocrine signaling. In obesity and type 2 diabetes (T2D), characteristic alterations reduced microbial diversity, depletion of fiber-fermenting taxa, expansion of mucus-degraders and pathobionts, and shifts in the virome/mycobiome associated with insulin resistance (IR) and glycemic dysregulation. Mechanistically, dysbiosis modifies production of short-chain fatty acids (SCFAs), bile-acid (BA) pools, and tryptophan-derived indoles; increases branched-chain amino acids and imidazole propionate; perturbs intestinal barrier integrity; and primes innate immunity via endotoxin (LPS) and other microbe-associated molecular patterns. These changes alter gut–brain and gut–liver axes, decrease GLP-1/peptide YY signaling, promote hepatic steatosis, and impair skeletal-muscle insulin signaling. Interventions that restore eubiosis, dietary fiber and polyphenols, Mediterranean/plant-forward patterns, time-restricted feeding, physical activity, and sleep regularity consistently improve metabolic endpoints. Clinical trials of pre-, pro-, and synbiotics show modest but reproducible benefits on IR and inflammatory markers; fecal microbiota transplantation (FMT) yields transient improvements in insulin sensitivity in selected recipients but lacks durable efficacy without diet/lifestyle co-intervention. Emerging strategies include defined microbial consortia, engineered commensals, bacteriophages, and targeted postbiotics (e.g., SCFA donors, secondary BA modulators). Precision microbiome medicine combining metagenomics, metatranscriptomics, metabolomics, and host genomics/immune profiling may identify responder endotypes and guide individualized therapy. This review synthesizes current evidence linking the gut ecosystem to obesity/T2D pathophysiology, maps metabolite and immune pathways to clinical phenotypes, and evaluates modulation strategies across lifestyle, nutritional, and microbial therapeutics, emphasizing pragmatic translation and safety.